Pfizer Price to Free Cash Flow Ratio 2010-2024 | PFE

Historical price to free cash flow ratio values for Pfizer (PFE) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Pfizer Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-05-17 28.64 32.01
2024-03-31 27.34 $0.89 30.56
2023-12-31 27.94 $0.84 33.28
2023-09-30 31.75 $1.42 22.37
2023-06-30 34.72 $1.85 18.76
2023-03-31 38.20 $3.53 10.83
2022-12-31 47.54 $4.54 10.47
2022-09-30 40.25 $4.10 9.82
2022-06-30 47.85 $4.97 9.63
2022-03-31 46.87 $5.55 8.44
2021-12-31 53.07 $5.23 10.14
2021-09-30 38.31 $5.21 7.35
2021-06-30 34.57 $3.73 9.27
2021-03-31 31.67 $2.39 13.26
2020-12-31 31.83 $2.16 14.72
2020-09-30 29.78 $1.87 15.92
2020-06-30 26.28 $2.29 11.46
2020-03-31 25.96 $2.12 12.24
2019-12-31 30.85 $1.86 16.61
2019-09-30 28.01 $1.99 14.11
2019-06-30 33.46 $2.07 16.19
2019-03-31 32.52 $2.27 14.34
2018-12-31 33.14 $2.32 14.31
2018-09-30 33.20 $2.68 12.40
2018-06-30 27.10 $2.63 10.31
2018-03-31 26.25 $0.38 68.85
2017-12-31 26.55 $0.98 26.97
2017-09-30 25.93 $0.63 40.93
2017-06-30 24.16 $0.42 57.06
2016-12-31 22.91 $2.33 9.82
2016-09-30 23.65 $2.15 11.01
2016-06-30 24.38 $2.21 11.05
2016-03-31 20.34 $2.30 8.86
2015-12-31 21.93 $2.12 10.32
2015-09-30 21.17 $2.25 9.39
2015-06-30 22.42 $2.16 10.40
2015-03-31 23.07 $2.13 10.81
2014-12-31 20.48 $2.47 8.28
2014-09-30 19.27 $2.37 8.12
2014-06-30 19.17 $2.61 7.34
2014-03-31 20.57 $2.51 8.20
2013-12-31 19.45 $2.39 8.14
2013-09-30 18.10 $2.27 7.97
2013-06-30 17.50 $2.00 8.73
2013-03-31 17.88 $2.01 8.89
2012-12-31 15.41 $2.05 7.50
2012-09-30 15.13 $2.04 7.42
2012-06-30 13.87 $1.94 7.16
2012-03-31 13.53 $2.15 6.30
2011-12-31 12.80 $2.36 5.42
2011-09-30 10.35 $2.49 4.16
2011-06-30 11.93 $2.75 4.34
2011-03-31 11.65 $2.60 4.48
2010-12-31 9.94 $1.23 8.07
2010-09-30 9.64 $1.08 8.89
2010-06-30 7.92 $0.86 9.23
2010-03-31 9.43 $0.93 10.12
2009-12-31 9.91 $2.18 4.54
2009-09-30 8.93 $1.82 4.89
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $163.878B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $732.877B 105.92
Novo Nordisk (NVO) Denmark $597.021B 45.88
Johnson & Johnson (JNJ) United States $371.302B 14.75
Merck (MRK) United States $331.494B 60.31
AbbVie (ABBV) United States $290.220B 14.99
AstraZeneca (AZN) United Kingdom $238.858B 20.76
Novartis AG (NVS) Switzerland $209.898B 14.88
Sanofi (SNY) $123.495B 11.65
Innoviva (INVA) United States $0.998B 7.01